Entering text into the input field will update the search result below

Veru crashes 65% as trading resumes after AdCom snub for COVID-19 therapy

Nov. 10, 2022 7:26 AM ETVeru Inc. (VERU) StockBy: Dulan Lokuwithana, SA News Editor6 Comments

Red arrow And dollar finance decline graph- Stock image

Baris-Ozer

  • Veru Inc. (NASDAQ:VERU), a biopharma targeting cancer, shed ~65% of its value on Thursday pre-market after a group of independent experts at the FDA voted against granting the emergency use authorization (EUA) for its oral COVID-19 therapy sabizabulin.
  • The

Recommended For You

About VERU Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VERU--
Veru Inc.